BioBlast Pharma (ORPN) Tops Q3 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St slips on rising bond yields; Walmart results weigh
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Lower Than Expected R&D Expenses Drive 3Q EPS Beat for BioBlast Pharma (ORPN); Oppenheimer Reiterates Outperform
November 19, 2015 7:33 AM ESTOppenheimer reiterated an Outperform rating and $32.00 price target on Bio Blast Pharma (NASDAQ: ORPN) following the company's 3Q earnings report. ORPN reported a loss of $(0.25)/share vs. consensus of $(0.29), primarily due to lower than expected R&D expenses. In 3Q15, ORPN announced positive... More
BioBlast Pharma (ORPN) Strengthens Leadership Through Organizational Changes; Oppenheimer Reiterates Outperform
November 16, 2015 2:09 PM ESTOppenheimer reiterated an Outperform rating and $32.00 price target on Bio Blast Pharma (NASDAQ: ORPN) following announced organizational changes. ORPN appointed Warren Wasiewski, M.D. as CMO and VP Research & Development, Leigh Cherry as VP Manufacturing, and Stacey Jurchison as VP Investor Relations & Corporate Communications.... More
